These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30275234)

  • 1. A Phase I/II Study of NAC with Docetaxel, Cisplatin, and S-1 for Stage III Gastric Cancer.
    Tanaka Y; Kunisaki C; Izumisawa Y; Makino H; Kimura J; Sato S; Miyamoto H; Kosaka T; Ono HA; Takahashi M; Sato K; Akiyama H; Endo I
    Anticancer Res; 2018 Oct; 38(10):6015-6021. PubMed ID: 30275234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial.
    Hosoda K; Azuma M; Katada C; Moriya H; Mieno H; Ishido K; Ema A; Ushiku H; Wada T; Washio M; Watanabe A; Higuchi K; Tanabe S; Koizumi W; Watanabe M; Yamashita K
    Gastric Cancer; 2019 May; 22(3):598-606. PubMed ID: 30284080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II Study of S-1 Plus Cisplatin Alternating With S-1 Plus Docetaxel in Patients With Advanced Gastric Cancer.
    Hosokawa A; Ando T; Ogawa K; Ueda A; Yoshita H; Mihara H; Fujinami H; Kajiura S; Yabushita K; Horikawa N; Kobayashi Y; Yoshioka A; Origasa H; Sugiyama T
    Am J Clin Oncol; 2018 Oct; 41(10):977-981. PubMed ID: 28930775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
    Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.
    Ito S; Sano T; Mizusawa J; Takahari D; Katayama H; Katai H; Kawashima Y; Kinoshita T; Terashima M; Nashimoto A; Nakamori M; Onaya H; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):322-331. PubMed ID: 27299887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer.
    Aoyama T; Nishikawa K; Fujitani K; Tanabe K; Ito S; Matsui T; Miki A; Nemoto H; Sakamaki K; Fukunaga T; Kimura Y; Hirabayashi N; Yoshikawa T
    Ann Oncol; 2017 Aug; 28(8):1876-1881. PubMed ID: 28486692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03.
    Okabe H; Hata H; Ueda S; Zaima M; Tokuka A; Yoshimura T; Ota S; Kinjo Y; Yoshimura K; Sakai Y;
    J Surg Oncol; 2016 Jan; 113(1):36-41. PubMed ID: 26604064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer.
    Migita K; Nashimoto A; Yabusaki H; Matsuki A; Aizawa M
    Int J Clin Oncol; 2016 Feb; 21(1):102-9. PubMed ID: 26017926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
    Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
    Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer.
    Uemura N; Kikuchi S; Sato Y; Ohnuma H; Okamoto K; Miyamoto H; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Okuda T; Minami S; Takahashi M; Okamoto T; Takada K; Miyanisi K; Takayama T; Kato J
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):707-713. PubMed ID: 28849257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
    Hirahara N; Matsubara T; Kaji S; Yamamoto T; Hyakudomi R; Takai K; Ishitobi K; Uchida Y; Tajima Y
    BMC Cancer; 2021 Oct; 21(1):1073. PubMed ID: 34598694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04-.
    Matsuda S; Takahashi T; Fukada J; Fukuda K; Kawakubo H; Saikawa Y; Kawaguchi O; Takeuchi H; Shigematsu N; Kitagawa Y
    Radiat Oncol; 2014 Jan; 9():9. PubMed ID: 24398302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
    Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
    J Surg Oncol; 2019 Jan; 119(1):56-63. PubMed ID: 30444009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer.
    Kinoshita J; Fushida S; Tsukada T; Oyama K; Okamoto K; Makino I; Nakamura K; Miyashita T; Tajima H; Takamura H; Ninomiya I; Ohta T
    Eur J Surg Oncol; 2015 Oct; 41(10):1354-60. PubMed ID: 26028256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer.
    Kurokawa Y; Hamakawa T; Miyazaki Y; Takahashi T; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Mori M; Doki Y
    Anticancer Res; 2015 Apr; 35(4):2223-8. PubMed ID: 25862882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study.
    Sato Y; Ohnuma H; Nobuoka T; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Shinya M; Katsuki S; Takahashi M; Maeda M; Okagawa Y; Naoki U; Kikuch S; Okamoto K; Miyamoto H; Shimada M; Takemasa I; Kato J; Takayama T
    Gastric Cancer; 2017 May; 20(3):517-526. PubMed ID: 27553665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of preoperative chemotherapy with docetaxel, cisplatin and S-1 for T4 locally advanced gastric cancer.
    Fushida S; Nashimoto A; Fukushima N; Kawachi Y; Fujimura T; Kuwabara S; Musha N;
    Jpn J Clin Oncol; 2012 Feb; 42(2):131-3. PubMed ID: 22167664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer.
    Sasaki K; Onodera S; Otsuka K; Satomura H; Kurayama E; Kubo T; Takahashi M; Ito J; Nakajima M; Yamaguchi S; Miyachi K; Kato H
    Med Oncol; 2017 Aug; 34(8):139. PubMed ID: 28707042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 2 Study of Induction Chemotherapy Using Docetaxel, Cisplatin, and S-1 for Gastric Cancer with Peritoneal Metastasis (KUGC06).
    Okabe H; Hata H; Hosogi H; Ueda S; Ota S; Kinjo Y; Hoshino N; Hisamori S; Tsunoda S; Obama K; Sakai Y;
    Ann Surg Oncol; 2019 Jun; 26(6):1779-1786. PubMed ID: 30767179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer.
    Mieno H; Yamashita K; Hosoda K; Moriya H; Higuchi K; Azuma M; Komori S; Yoshida T; Tanabe S; Koizumi W; Katada N; Watanabe M
    Surg Today; 2017 Oct; 47(10):1249-1258. PubMed ID: 28365892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.